Sinphar Pharmaceutical Co.,Ltd. (1734.TW)
TWD 31.55
(-0.94%)
TWD 31.55
(-0.94%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.25 Billion TWD | 1.07% |
| 2022 | 6.18 Billion TWD | -0.57% |
| 2021 | 6.22 Billion TWD | 1.53% |
| 2020 | 6.12 Billion TWD | 3.56% |
| 2019 | 5.91 Billion TWD | 0.65% |
| 2018 | 5.87 Billion TWD | -2.73% |
| 2017 | 6.04 Billion TWD | -2.63% |
| 2016 | 6.2 Billion TWD | -2.82% |
| 2015 | 6.38 Billion TWD | -1.2% |
| 2014 | 6.46 Billion TWD | 13.33% |
| 2013 | 5.7 Billion TWD | 24.81% |
| 2012 | 4.56 Billion TWD | -1.49% |
| 2011 | 4.63 Billion TWD | 24.92% |
| 2010 | 3.71 Billion TWD | 3.6% |
| 2009 | 3.58 Billion TWD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 6.4 Billion TWD | 0.98% |
| 2024 Q1 | 6.34 Billion TWD | 1.46% |
| 2023 FY | 6.25 Billion TWD | 1.07% |
| 2023 Q4 | 6.25 Billion TWD | 1.44% |
| 2023 Q3 | 6.16 Billion TWD | 3.11% |
| 2023 Q1 | 5.96 Billion TWD | -3.49% |
| 2023 Q2 | 5.97 Billion TWD | 0.12% |
| 2022 Q3 | 6.13 Billion TWD | -1.41% |
| 2022 Q1 | 6.35 Billion TWD | 2.19% |
| 2022 FY | 6.18 Billion TWD | -0.57% |
| 2022 Q4 | 6.18 Billion TWD | 0.82% |
| 2022 Q2 | 6.22 Billion TWD | -2.11% |
| 2021 Q1 | 6.42 Billion TWD | 4.9% |
| 2021 Q4 | 6.22 Billion TWD | 0.33% |
| 2021 FY | 6.22 Billion TWD | 1.53% |
| 2021 Q3 | 6.2 Billion TWD | -1.94% |
| 2021 Q2 | 6.32 Billion TWD | -1.62% |
| 2020 Q3 | 6.14 Billion TWD | -1.95% |
| 2020 FY | 6.12 Billion TWD | 3.56% |
| 2020 Q4 | 6.12 Billion TWD | -0.24% |
| 2020 Q1 | 6.18 Billion TWD | 4.61% |
| 2020 Q2 | 6.26 Billion TWD | 1.2% |
| 2019 Q2 | 6.23 Billion TWD | 5.42% |
| 2019 FY | 5.91 Billion TWD | 0.65% |
| 2019 Q4 | 5.91 Billion TWD | -2.14% |
| 2019 Q3 | 6.04 Billion TWD | -2.99% |
| 2019 Q1 | 5.91 Billion TWD | 0.56% |
| 2018 Q4 | 5.87 Billion TWD | -1.07% |
| 2018 Q1 | 6.01 Billion TWD | -0.45% |
| 2018 Q2 | 6.03 Billion TWD | 0.3% |
| 2018 FY | 5.87 Billion TWD | -2.73% |
| 2018 Q3 | 5.94 Billion TWD | -1.53% |
| 2017 Q4 | 6.04 Billion TWD | 0.74% |
| 2017 FY | 6.04 Billion TWD | -2.63% |
| 2017 Q2 | 5.97 Billion TWD | -0.15% |
| 2017 Q3 | 5.99 Billion TWD | 0.47% |
| 2017 Q1 | 5.98 Billion TWD | -3.65% |
| 2016 Q1 | 6.21 Billion TWD | -2.76% |
| 2016 Q4 | 6.2 Billion TWD | -2.91% |
| 2016 Q2 | 6.26 Billion TWD | 0.95% |
| 2016 Q3 | 6.39 Billion TWD | 1.96% |
| 2016 FY | 6.2 Billion TWD | -2.82% |
| 2015 Q4 | 6.38 Billion TWD | 5.49% |
| 2015 Q3 | 6.05 Billion TWD | -3.76% |
| 2015 Q1 | 6.42 Billion TWD | -0.55% |
| 2015 Q2 | 6.29 Billion TWD | -2.13% |
| 2015 FY | 6.38 Billion TWD | -1.2% |
| 2014 Q2 | 5.79 Billion TWD | 1.17% |
| 2014 Q3 | 5.61 Billion TWD | -3.19% |
| 2014 FY | 6.46 Billion TWD | 13.33% |
| 2014 Q4 | 6.46 Billion TWD | 15.21% |
| 2014 Q1 | 5.72 Billion TWD | 0.44% |
| 2013 Q4 | 5.7 Billion TWD | 4.74% |
| 2013 FY | 5.7 Billion TWD | 24.81% |
| 2013 Q2 | 5.25 Billion TWD | 1.61% |
| 2013 Q1 | 5.17 Billion TWD | 13.28% |
| 2013 Q3 | 5.44 Billion TWD | 3.53% |
| 2012 Q2 | 4.29 Billion TWD | 3.17% |
| 2012 FY | 4.56 Billion TWD | -1.49% |
| 2012 Q1 | 4.15 Billion TWD | -10.34% |
| 2012 Q3 | 4.49 Billion TWD | 4.86% |
| 2012 Q4 | 4.56 Billion TWD | 1.57% |
| 2011 Q4 | 4.63 Billion TWD | 25.91% |
| 2011 Q1 | 3.76 Billion TWD | 1.42% |
| 2011 Q2 | 3.69 Billion TWD | -1.89% |
| 2011 FY | 4.63 Billion TWD | 24.92% |
| 2011 Q3 | 3.68 Billion TWD | -0.29% |
| 2010 Q4 | 3.71 Billion TWD | 0.0% |
| 2010 FY | 3.71 Billion TWD | 3.6% |
| 2009 FY | 3.58 Billion TWD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Apex Biotechnology Corp. | 2.29 Billion TWD | -172.141% |
| Panion & Bf Biotech Inc. | 3.23 Billion TWD | -93.222% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 5.17 Billion TWD | -20.872% |
| GenMont Biotech Incorporation | 1.65 Billion TWD | -278.124% |
| Abnova (Taiwan) Corporation | 1.35 Billion TWD | -361.082% |
| Adimmune Corporation | 9.48 Billion TWD | 34.091% |
| Tanvex BioPharma, Inc. | 2.76 Billion TWD | -126.21% |
| Polaris Group | 9.09 Billion TWD | 31.291% |
| Energenesis Biomedical CO.,LTD. | 828.57 Million TWD | -654.442% |
| UnicoCell Biomed Co., Ltd. | 685.92 Million TWD | -811.331% |
| PELL Bio-Med Technology Co. Ltd. | 1.41 Billion TWD | -340.789% |